Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Receivables (2016 - 2025)

Cytosorbents' Receivables history spans 15 years, with the latest figure at $14.7 million for Q4 2025.

  • Quarterly results put Receivables at $14.7 million for Q4 2025, up 13.58% from a year ago — trailing twelve months through Dec 2025 was $14.7 million (up 13.58% YoY), and the annual figure for FY2025 was $14.7 million, up 13.58%.
  • Receivables for Q4 2025 was $14.7 million at Cytosorbents, up from $13.4 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $14.7 million in Q4 2025 to a low of $7.5 million in Q4 2021.
  • The 5-year median for Receivables is $11.0 million (2023), against an average of $10.9 million.
  • Peak annual rise in Receivables hit 53.12% in 2021, while the deepest fall reached 7.75% in 2021.
  • Year by year, Receivables stood at $7.5 million in 2021, then grew by 26.09% to $9.5 million in 2022, then rose by 19.71% to $11.4 million in 2023, then grew by 13.76% to $12.9 million in 2024, then increased by 13.58% to $14.7 million in 2025.
  • According to Business Quant data, Receivables over the past three periods came in at $14.7 million, $13.4 million, and $14.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.